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Summary
Background Directly observed treatment (DOT) has been the standard of care for tuberculosis since the early 1990s, but 
it is inconvenient for patients and service providers. Video-observed therapy (VOT) has been conditionally recommended 
by WHO as an alternative to DOT. We tested whether levels of treatment observation were improved with VOT.
Methods We did a multicentre, analyst-blinded, randomised controlled superiority trial in 22 clinics in England (UK). 
Eligible participants were patients aged at least 16 years with active pulmonary or non-pulmonary tuberculosis who 
were eligible for DOT according to local guidance. Exclusion criteria included patients who did not have access to 
charging a smartphone. We randomly assigned participants to either VOT (daily remote observation using a 
smartphone app) or DOT (observations done three to five times per week in the home, community, or clinic settings). 
Randomisation was done by the SealedEnvelope service using minimisation. DOT involved treatment observation by 
a health-care or lay worker, with any remaining daily doses self-administered. VOT was provided by a centralised 
service in London. Patients were trained to record and send videos of every dose ingested 7 days per week using a 
smartphone app. Trained treatment observers viewed these videos through a password-protected website. Patients 
were also encouraged to report adverse drug events on the videos. Smartphones and data plans were provided free of 
charge by study investigators. DOT or VOT observation records were completed by observers until treatment or study 
end. The primary outcome was completion of 80% or more scheduled treatment observations over the first 2 months 
following enrolment. Intention-to-treat (ITT) and restricted (including only patients completing at least 1 week of 
observation on allocated arm) analyses were done. Superiority was determined by a 15% difference in the proportion of 
patients with the primary outcome (60% vs 75%). This trial is registered with the International Standard Randomised 
Controlled Trials Number registry, number ISRCTN26184967.
Findings Between Sept 1, 2014, and Oct 1, 2016, we randomly assigned 226 patients; 112 to VOT and 114 to DOT. 
Overall, 131 (58%) patients had a history of homelessness, imprisonment, drug use, alcohol problems or mental health 
problems. In the ITT analysis, 78 (70%) of 112 patients on VOT achieved ≥80% scheduled observations successfully 
completed during the first 2 months compared with 35 (31%) of 114 on DOT (adjusted odds ratio [OR] 5·48, 95% CI 
3·10–9·68; p<0·0001). In the restricted analysis, 78 (77%) of 101 patients on VOT achieved the primary outcome 
compared with 35 (63%) of 56 on DOT (adjusted OR 2·52; 95% CI 1·17–5·54; p=0·017). Stomach pain, nausea, and 
vomiting were the most common adverse events reported (in 16 [14%] of 112 on VOT and nine [8%] of 114 on DOT).
Interpretation VOT was a more effective approach to observation of tuberculosis treatment than DOT. VOT is likely to 
be preferable to DOT for many patients across a broad range of settings, providing a more acceptable, effective, and 
cheaper option for supervision of daily and multiple daily doses than DOT.
Funding National Institute for Health Research. 
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Directly observed treatment (DOT) has been the standard 
of care for tuberculosis since the early 1990s.1,2 It arose 
from early observations that irregular treatment could 
threaten clinical outcomes and public health through 
generation of drug resistance, relapse, and transmission 
of infection.3 DOT is currently recommended by WHO4 
and the American Thoracic Society.5 In England (UK) it 
is advised for patients at high risk of poor adherence,6 
including those with clinically complex disease, 
multidrug-resistant (MDR) tubercu losis, mental health 
problems, previous tuberculosis treatment, or poor 
adherence.6 DOT is also advised for socially complex 
groups (eg, people with history of homelessness, 
imprisonment, or drug use or alcohol problems).
Although DOT can be administered in clinic, 
community, or home settings, it still entails substantial 
inconvenience to patients and service providers. 7-day 
treatment regimens are therefore generally administered 
through DOT 5 days per week and self-administered 
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treatment at the weekend. Regimens given three times 
per week have also been approved with DOT and are used 
in England,6 although they are not currently recommended 
by WHO because of increased risk of treatment failure 
possibly because treatment is given less frequently.4
Developments in video telephony technology have raised 
the possibility of remote video-observed treatment (VOT) 
as an alternative approach to DOT.7 Initially, this required a 
live video call (synchronous VOT) between the patient 
and observer.8–13 More recently, smartphone apps have 
been developed that enable video clips to be recorded 
and forwarded for later viewing (asynchronous VOT).14 
Asynchronous VOT is currently used in some clinics in the 
USA and has high reported levels of patient acceptability, 
decreased costs compared with DOT, and programmatic 
evidence of effectiveness.14–18 WHO therefore conditionally 
recom mended VOT as an alternative to DOT in 2017, but 
the evidence was graded weak due to few randomised 
controlled trials available.4 Additionally, VOT has yet to be 
assessed in socially complex patients. Here, we report 
results from a randomised trial comparing treatment 
observation with asynchronous VOT versus in-person 
DOT for supporting treatment adherence in patients with 
active tuberculosis in England.
Methods
Study design and participants
We did a multicentre, analyst-blinded, randomised 
controlled, superiority trial at 22 clinics in England (UK; 
London [17 sites], Birmingham [three], Coventry [one], 
and Leicester [one]). Ethical approval was granted by the 
National Research Ethics Service Committee East of 
England—Essex, Research Ethics Committee, 20/03/2014, 
ref: 10/H0302/51. The full trial protocol is published on 
the International Standard Randomised Controlled Trial 
Number Registry).
Eligible patients were identified by case managers at 
each participating clinic and referred to the study team. 
Inclusion criteria included patients aged 16 years or older 
with active pulmonary or non-pulmonary tuberculosis 
who were eligible for DOT according to UK national 
guidance.6 Patients were invited to participate regardless 
of whether they had previously agreed to treatment 
observation. Patients were excluded if they were not 
suitable for VOT because they did not have access to 
facilities to charge a smartphone. They were also 
excluded if they had less than 2 months remaining on 
their treatment regimen, because the primary study 
outcome required measurement of adherence over 
2 months. Patients with MDR tuberculosis were excluded 
Research in context
Evidence before this study
We searched PubMed for studies published before 
22 March, 2018, using the search terms “tuberculosis” AND 
(“video” OR “mobile”) AND “observe/observation”. 11 studies 
described implementation of synchronous (six) or asynchronous 
(five) video-observed therapy (VOT). Most studies were pilot 
projects assessing feasibility and acceptability of using VOT. 
They showed that VOT is an acceptable, flexible, cost-effective 
and patient-friendly intervention. Two cohort studies compared 
treatment observation levels for directly observed treatment 
(DOT) and synchronous VOT; one, a study in South Australia, 
reported 87·9% of treatment events observed for VOT and 
68·9% for DOT; the second, a study in New York City, reported 
95% adherence for VOT and 91% for DOT. No comparative 
studies have been published for asynchronous VOT.
Added value of this study
This is the first randomised controlled trial comparing the level 
of treatment observation for DOT and asynchronous VOT. 
A higher proportion of patients on VOT completed 80% or 
more scheduled treatment observations over the first 2 months 
following enrolment than those on DOT. The study also showed 
that VOT was cheaper to deliver than DOT.
Implications of all the available evidence
VOT is a more effective and cheaper approach to observation 
of tuberculosis treatment than DOT. The intervention has been 
acceptable when assessed in patients in various settings 
including North America, England (UK), Belarus, Kenya, 
and Vietnam.
For the trial protocol see 
DOI:10.1186/ISRCTN26184967
Figure 1: Enrolment and randomisation
MDR=multi-drug resistant. *The most common other reason for not enrolling 
patients (32 of 45) was clinic staff considering that the patient needed intensive 
face-to-face support for emotional, medical, or physical reasons, or because of 
imminent risk of loss to follow-up. Characteristics of eligible patients who were 
approached but refused to take part in the study are in the appendix.
322 excluded
98 did not meet inclusion 
criteria





548 assessed for eligibility
114 allocated to DOT
56 ≥1 week of DOT
58 <1 week of DOT 
114 intention-to-treat analysis 
56 restricted analysis
112 allocated to VOT
101 ≥1 week of VOT
11 <1 week of VOT 
112 intention-to-treat analysis 
101 restricted analysis
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because they require twice-daily treatment (these patients 
were recruited into a non-randomised study, that will 
be reported separately). All patients provided written 
informed consent to participate in the study.
Randomisation and masking
We randomly assigned participants to either asyn-
chronous VOT or DOT based in a clinic, community 
(eg, pharmacy or hostel), or home setting. Randomisation 
was provided by SealedEnvelope), a telephone and 
online software application used for randomly assigning 
patients in clinical trials. The system used randomisation 
by minim isation19 to ensure balance across study sites 
and the stage of treatment at the time of enrolment 
(ie, within the first 2 months of treatment and after the 
first 2 months of treatment). Minimisation allocates 
patients to best maintain balance in the stratification 
factors by calculating an imbalance score at each 
randomisation. It then assigns with higher probability 
each patient to the treatment that will reduce the 
imbalance.
Procedures
DOT was delivered according to usual clinical practice.6 
This involved treatment observation three to five times 
per week by a health-care or lay worker, with the 
remaining daily doses self-administered. VOT was 
provided by a centralised service in London (UK). Patients 
were trained to record and send videos of every dose 
ingested 7 days per week using a smartphone app 
developed by researchers at the University of California 
(San Diego, CA, USA).14 Trained treatment observers 
viewed the videos through a password-protected website. 
As a safety precaution, to address concerns that reduced 
face-to-face contact might lead to side-effects being 
undetected, patients were also encouraged to report 
adverse drug events on the videos. Smartphones 
(Samsung Galaxy S3/S4/Xcover3) and data plans 
(including UK calls and texts) were provided free of 
charge, paid by the study at commercial rates. Patients 
signed a form agreeing to return the phone at the end 
of treatment (details on returning the phones in the 
appendix). DOT and VOT observation records were 
completed by observers until treatment or study end. Full 
details of interventions are in the appendix.
Outcomes
The primary outcome was successful completion of 
80% or more of scheduled treatment observations in 
the 2 months following randomisation. The proportion 
of sched uled obser vations (measured on a continuous 
scale) successfully completed in the 2 months following 
enrolment, and throughout treatment, was a secondary 
outcome.
Other secondary outcome measures were: sputum 
culture results at 2 months post-treatment initiation; 
treatment outcomes; occurrence of adverse events; 
numbers of hospitalisations; staff time spent observing or 
travelling to observe patients; staff time and cost of travel 
when re-engaging patients; cost of treatment observation; 
patient satisfaction, resource use, and health-related 
quality of life.
Semi-structured interviews were done with 16 patients 
selected to represent a range of backgrounds and VOT 
and DOT successes and failures. Full results of the 
qualitative analysis will be reported separately. Details of 










16–34 61 (54%) 27 (48%) 64 (57%) 58 (57%)
35–54 45 (40%) 22 (39%) 35 (31%) 32 (32%)
≥55 8 (7%) 7 (13%) 13 (12%) 11 (11%)
Sex
Male 83 (73%) 42 (75%) 82 (73%) 73 (72%)
Female 31 (27%) 14 (25%) 30 (27%) 28 (28%)
Born in the UK
No 83 (73%) 37 (66%) 93 (83%) 85 (84%)
Yes 31 (27%) 19 (34%) 19 (17%) 16 (16%)
Previous tuberculosis
No 82 (72%) 40 (71%) 85 (76%) 75 (74%)
Yes 30 (26%) 15 (27%) 27 (24%) 26 (26%)
Pulmonary
No 41 (36%) 19 (34%) 43 (38%) 39 (39%)
Yes 73 (64%) 37 (66%) 69 (62%) 62 (61%)
Social risk factor†
Never 48 (42%) 15 (27%) 47 (42%) 44 (44%)
>5 years ago 19 (17%) 10 (18%) 19 (17%) 16 (16%)
Within 5 years 47 (41%) 31 (55%) 46 (41%) 41 (41%)
Homeless
Never 77 (68%) 31 (55%) 70 (63%) 64 (63%)
>5 years ago 14 (12%) 10 (18%) 16 (14%) 15 (15%)
Within 5 years 23 (20%) 15 (27%) 24 (21%) 20 (20%)
Prison
Never 93 (82%) 44 (79%) 97 (87%) 89 (88%)
>5 years ago 9 (8%) 7 (13%) 8 (7%) 6 (6%)
Within 5 years 11 (10%) 4 (7%) 7 (6%) 6 (6%)
Drug use
Never 96 (84%) 44 (79%) 89 (80%) 82 (81%)
>5 years ago 2 (2%) 2 (4%) 4 (4%) 3 (3%)
Within 5 years 15 (13%) 10 (18%) 18 (16%) 15 (15%)
Alcohol problems
No 91 (80%) 38 (68%) 92 (82%) 83 (82%)
Yes 21 (18%) 18 (32%) 17 (15%) 15 (15%)
Mental health problems
No 94 (83%) 44 (79%) 94 (84%) 87 (86%)
Yes 18 (16%) 12 (21%) 14 (13%) 10 (10%)
Data shown by allocated intervention and initial engagement (at least 1 week on allocated intervention). *Initial 
engagement with intervention (at least 1 week of observation in allocated arm). †History of homelessness, 
imprisonment, drug use or alcohol problems, or mental health problems.
Table 1: Baseline characteristics of the study population
See Online for appendix
For more on SealedEnvelope see 
http://www.sealedenvelope.com/
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the methods used for collection of the additional 
outcomes are in the appendix.
Statistical analysis
We determined that a sample of 200 patients per arm 
would provide a power of 90% to detect a 15% difference 
in the proportion of patients with the primary outcome 
(60% vs 75%). This was based on a two-sided significance 
level of 5%. Following a review of study progress, 
the funder’s study monitoring com mittee requested 
an interim analysis, the plan for which was published 
on the International Standard Random ised Controlled 
Trial Number Registry before analysis. It included a 
stopping rule using the Haybittle–Peto boundary 
of 0·001 for the primary outcome. We used the 
approach described in the interim analysis plan for the 
final analysis. This involved main and sensitivity 
analyses for intention-to-treat (ITT) and restricted 
groups, described below and summarised in the 
appendix.
In the main analysis, VOT treatment observations were 
classified as successfully completed if ingestion of all 
medicines was observed, or if video clips were received 
but not viewable because of a technical complication 
(since patients had no control over whether videos 
were corrupted). The sensitivity analysis considered 
only videos for which all medicines were observed as 
successfully completed. The ITT analysis included all 
patients, analysed according to the arm to which they 
were originally randomised. The restricted analysis 
excluded patients with less than 1 week of observation in 
the allocated arm. This was designed to include only 
those patients who had, at least initially, engaged with the 
allocated intervention.
We used logistic regression to analyse the primary 
outcome and linear regression for the secondary 
outcomes. Time since start of treatment, age, and sex 
were considered a priori as potential confounders and 
included in all models. For the restricted analysis, we 
also considered covariates that might have affected 
initial engagement with the allocated intervention 
(homelessness, imprisonment, drug use, alcohol prob-
lems, immigration concerns, mental health problems, 
previous loss to follow-up, and no recourse to public 
funds). All analyses accounted for clustering at the level 
of the clinic using robust standard errors.20 Likelihood 
ratio tests for interaction were used to assess evidence of 
differing effect size in population subgroups. Analyses 
were done using Stata (version 14) and R (version 3.3.2) 
software. This trial is registered with the International 
Standard Randomised Controlled Trials Number registry, 
number ISRCTN26184967.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between Sept 1, 2014, and Oct 1, 2016, we screened 
548 patients with tuberculosis for eligibility. Of these, 
322 (59%) were ineligible and 226 (41%) were randomly 
assigned to the study groups (figure 1). Follow-up 
continued until Dec 31, 2016. ITT analyses included 
112 to VOT and 114 patients assigned to DOT.
Patients were mainly young adults born outside the UK 
(table 1). A high proportion had a history of homelessness, 
imprisonment, drug use, alcohol problems, or mental 
health problems. Baseline characteristics were similar 
between the two groups. Patients were substantially 
more likely to engage initially (ie, have at least 1 week of 
Figure 2: Level of observation
Each row represents one patient. Each dot represents one scheduled treatment observation day. Observed (black) 
and unobserved (grey) scheduled doses are shown for each patient in the study through the course of follow-up. 
Patients are ordered according to their length of treatment time remaining after randomisation.







For more on the interim 
analysis plan see https://doi.
org/10.1186/ISRCTN26184967
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follow-up) with VOT (101 [90%] of 112) than DOT (56 [49%] 
of 114). Levels of initial engagement with VOT exceeded 
70% in all subgroups, but with DOT were particularly 
low (<50%) in younger adults, foreign-born patients 
and those without social risk factors or mental health 
problems (table 1). Amongst the 56 patients who initially 
engaged with DOT, 27 (48%) had home-based DOT, 
20 (36%) clinic-based, and nine (16%) community based 
(eg, a local pharmacy). DOT was scheduled three times 
per week for 14 patients, and five times per week for the 
remainder. The level of observation achieved in each 
study arm is in figure 2. In the ITT analysis, 78 (70%) of 
122 patients on VOT successfully achieved the primary 
outcome (≥80% scheduled observations successfully 
completed during the first 2 months), compared with 
35 (31%) of 114 patients on DOT: partially adjusted odds 
ratio (OR) 5·48, 95% CI, 3·10–9·68; p<0·0001 (table 2).
For the secondary outcome of the proportion of 
scheduled observations successfully completed over 
the first 2 months, in the ITT analysis, 5091 (79%) of 
6474 scheduled observations were successfully completed 
on VOT, compared with 1774 (45%) of 3922 on DOT. 
The mean proportions of doses observed per patient 
were 78% (41%) for VOT and 36% (SD 31%) for DOT 
(adjusted mean difference in proportions 41%, 95% CI 
29–53; p<0·0001). In the restricted analysis, the overall 
proportions were 5091 (86% [SD 17%]) of 5893 for VOT 
and 1774 (73% [27%]) of 2418 for DOT (adjusted mean 
difference in proportions 14%, 95% CI 7–20; p<0·0001). 
Full results for this secondary outcome are in the appendix.
High observation rates were maintained in the VOT 
arm, but they rapidly decreased in the DOT arm 
(figure 3). Over the full follow-up period (up to 6 months) 
12 422 (77%; 95% CI 76–77) of 16 230 scheduled 
observations were completed in the VOT arm compared 
with 3884 (39%; 38–40) of 9882 scheduled observations 
in the DOT arm (p<0·0001). In the restricted analysis, 
over the full follow-up period 12 422 (83%; 83–84) of 
14 907 of scheduled observations were completed in the 
VOT arm compared with 3884 (61%; 60–62) of 6351 in 
the DOT arm (p<0·0001). Observation completion 
rates were higher for VOT than DOT in all subgroups 
(table 3). There were no significant differences in positive 
sputum cultures at 2 months following treat ment onset, 
treatment com pletion, loss to follow-up or numbers 
of hospital admissions between trial arms (appendix). 
368 adverse events were reported by 32 patients on VOT 
and 184 reported by 15 on DOT (table 4). 169 unscheduled 
Figure 3: Proportions of patients with 80% or more of scheduled doses observed through treatment
Numbers above bars are the numbers of patients who had scheduled treatment observations in each month following 
randomisation and the numbers who completed 80% or more scheduled observations. Error bars are 95% CIs.
n (%) with primary outcome* Unadjusted Partially adjusted† Fully adjusted
DOT VOT OR 
(95% CI)
p value Adjusted OR 
(95% CI)




Total 114 112 ·· ·· ·· ·· ·· ··
Main‡ 35 (31%) 78 (70%) 5·18 (2·94–9·12) <0·0001 5·48 (3·10–9·68) <0·0001 ·· ··
Sensitivity 35 (31%) 68 (61%) 3·49 (2·01–6·04) <0·0001 3·60 (1·91–6·79) <0·0001 ·· ··
Restricted§
Total 56 101 ·· ·· ·· ·· ·· ··
Main 35 (63%) 78 (77%) 2·03 (1·00–4·15) 0·051 2·23 (1·16–4·27) 0·016 2·52 (1·17–5·47) 0·019
Sensitivity 35 (63%) 68 (67%) 1·24 (0·62–2·45) 0·542 1·29 (0·71–2·34) 0·398 1·44 (0·75–2·75) 0·273
Data shown by trial arm for intention-to-treat and restricted analyses. DOT=directly observed treatment. VOT=video-observed therapy. OR=odds ratio. *Primary outcome: 
patients who had ≥80% observations successfully completed in the first 2 months following randomisation. †Partially-adjusted models adjusted for time since start of 
treatment, age, sex, and treatment. Fully-adjusted models (for restricted analysis only) additionally adjusted for current social risk factor (homelessness, imprisonment, drug use, 
alcohol problems, immigration concern), ever lost to follow-up, no recourse to public funds, mental health problems. ‡Main analysis: VOT treatment observations were classified 
as successfully completed if ingestion of all medicines was observed, or if video clips were received but not viewable due to a technical complication. Sensitivity analysis: only 
videos for which ingestion of all medicines was observed were classified as successfully completed. §Restricted analysis included only patients who engaged initially (had at least 
1 week of observation) on the allocated treatment arm.
Table 2: Numbers and proportions of patients and results of logistic regression analysis for the primary outcome
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outpatient appointments were made by 47 patients on 
VOT, compared with 233 by 42 patients on DOT.
Average staff time per dose observed was 56 min 
(SD 54) for community based DOT (including travel 
time); 15 min (12) for clinic-based DOT, and 3·2 min 
(0·5) for VOT. Patients on DOT spent a mean 29 min 
(SD 48) per week on treatment observation (including 
travelling to or from clinics, waiting for appointments, 
and appointment time). Those on VOT spent a mean of 
1·8 min (2·2) setting up and recording each video.
The costs of providing DOT over 6 months were 
estimated at £5700 per patient for observations five times 
per week, and £3420 for observations three times 
per week. For daily VOT over 6 months, costs were 
estimated at £1645 per patient (in a service managing 
50 patients; appendix). 
The sensitivity analysis excluding corrupted videos 
showed similar effects (table 2), as did the main restricted 
analysis.
Discussion
In this trial, VOT enabled higher levels of treatment 
observation for patients with tuberculosis, both over the 
first 2 months of treatment and throughout treatment, 
than DOT. VOT also supported daily dosing, was effective 
for socially complex populations, and had a lower drop-
out rate than DOT. The absence of face-to-face contact 
did not reduce the identification of adverse events or lead 
to more unscheduled appointments. VOT reduced staff 
time requirements, especially compared with home-
based DOT, making VOT cheaper than DOT even after 
taking into account the costs of the telephones and data 
plans provided by the study.
Systematic reviews and meta-analyses draw differing 
conclusions about the effectiveness of DOT.21,22 However, 
one review showed that DOT increased treatment 
success, adherence, and 2-month sputum conversion, 
and decreased loss to follow-up and acquired drug res-
istance compared with self-administered treatment.4 
Community based DOT was more effective than 
hospital-based or clinic-based DOT, highlighting the 








(Continued from previous column)
Prison
Never 93 26 (28%) 97 68 (70%) 0·443
>5 years ago 9 5 (56%) 8 5 (63%) ··
Within 5 years 11 3 (27%) 7 5 (71%) ··
Unknown 1 1 (100%) 0 ·· ··
Drug use
Never 96 27 (28%) 89 65 (73%) 0·606
>5 years ago 2 2 (100%) 4 3 (75%) ··
Within 5 years 15 6 (40%) 18 9 (50%) ··
Unknown 1 0 1 1 (100%) ··
Alcohol problems
No 91 22 (24%) 92 66 (72%) 0·545
Yes 21 13 (62%) 17 12 (71%) ··
Unknown 2 0 3 0 ··
Mental health problems
No 94 28 (30%) 94 67 (71%) 0·866
Yes 18 7 (39%) 14 8 (57%) ··
Unknown 2 0 4 3 (75%) ··
Immigration concerns
No 102 32 (31%) 99 70 (71%) 0·761
Yes 9 2 (22%) 9 5 (56%) ··
Unknown 3 1 (33%) 4 3 (75%) ··
Data shown by trial arm and baseline characteristics. DOT=directly observed 
treatment. VOT=video-observed therapy. *History of homelessness, 
imprisonment, drug use or alcohol problems, or mental health problems
Table 3: Numbers and proportions of patients with more than 80% of 








Total 114 35 (31%) 112 78 (69%) ··
Age group (years)
16–34 61 15 (25%) 62 45 (73%) 0·439
35–54 45 16 (36%) 35 25 (71%) ··
≥55 8 4 (50%) 13 8 (62%) ··
Sex
Male 83 29 (35%) 82 60 (73%) 0·363
Female 31 6 (19%) 30 18 (60%) ··
Born in the UK
No 83 22 (27%) 93 66 (71%) 0·430
Yes 31 13 (42%) 19 12 (63%) ··
Previous tuberculosis
No 82 25 (31%) 85 58 (68%) 0·463
Yes 30 9 (30%) 27 20 (74%) ··
Unknown 2 1 (50%) 0 ·· ··
Site of disease
Pulmonary only 60 20 (33%) 55 37 (67%) 0·662
Pulmonary and 
extrapulmonary
13 5 (39%) 14 11 (79%) ··
Extrapulmonary 
only
41 10 (24%) 43 30 (70%) ··
Social risk factor (any)*
Never 48 8 (17%) 47 35 (75%) 0·0808
>5 years ago 19 6 (32%) 19 11 (58%) ··
Within 5 years 47 21 (45%) 46 32 (70%) ··
Homeless
Never 77 19 (25%) 70 49 (70%) 0·179
>5 years ago 14 7 (50%) 16 10 (63%) ··
Within 5 years 23 9 (39%) 24 17 (71%) ··
Unknown 0 ·· 2 2 (100%) ··
(Table 3 continues in next column)
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The review also showed that DOT was more effective 
when delivered by health staff or lay workers than by 
family members.4 VOT provides the technology to 
support professional treatment observation that is more 
convenient and cheaper than in-person DOT. In this 
study, VOT had a much higher uptake rate than DOT 
(91% vs 46%). This is a clear indication that providing 
treatment observation in a more convenient, flexible, 
and less intrusive way makes VOT a more acceptable 
mode of treatment for many patients.
VOT, as used in this study, has a wide range of 
components beyond convenience of observation. The 
intervention included personal support, where patients 
met the VOT observer for training, and received regular 
personalised messages as reminders, confirmation of 
receipt of video clips, or to follow up when clips were not 
received. Patients were specifically asked to report any 
adverse events after each clip and the observers also 
supported onward referral to deal with reported adverse 
events. Numerically more adverse events were reported 
in the VOT group than in the DOT group, which was 
likely due to the systematic reporting, although it could 
also have resulted from better compliance. Patients were 
provided with a smartphone with a data plan, and free 
domestic calls and text messages. This acted facilitated 
easy communication and improved access to care 
providers, and was a material incentive that was valued 
by patients although patients were asked to return the 
smartphone on completion of the study. On average, 
fewer than one phone was needed per patient because 
phones were re-used throughout the trial.
The trial had several limitations. It was not possible 
to blind patients or treatment observers to the inter-
vention, although the investigators and statistician were 
blinded during the analysis. We could not distinguish 
between doses that were not observed and doses that 
were not taken. Case managers reported that many of 
the unobserved scheduled doses for DOT had previously 
been negotiated with clinic case managers because of 
patients having conflicting appointments or priorities, 
or case managers choosing to trust patients to self-
administer scheduled doses. Approximately 7% of video 
clips submitted during the first 2 months of treatment 
were corrupted because of a software bug that was 
subsequently fixed (appendix). In our main analysis we 
assumed that submission of a corrupted clip represented 
pill ingestion since patients were not aware that the 
videos they submitted were corrupted. We tested the 
potential impact of this assumption in sensitivity 
analysis A (appendix) which regarded corrupted clips as 
unobserved. This sensitivity analysis produced similar 
results to the main analysis.
ORs reported through logistic regression should not 
be regarded as accurate estimates of relative risk. For 
example, our adjusted OR for the main analysis is 5·48 
but the corresponding unadjusted relative risk would 
be 2·27. The primary outcome (observing 80% scheduled 
doses) could be considered to be biased in favour of DOT, 
because it required substantially more VOT doses 
(scheduled 7 days per week) to be observed than DOT 
doses (scheduled three or five times per week). The 
restricted analysis further favoured DOT, because it 
included only the highly selected subset of patients 
allocated to DOT who were willing to be observed. That 
VOT still outperformed DOT under these constraints, 
especially when considered over 6 months, adds to the 
robustness of the findings.
The study was not powered to detect differences in 
culture conversion rate, treatment completion, loss to 
follow-up, relapse, or development of drug resistance. 
Nevertheless, it is reasonable to assume that improved 
adherence might improve all these outcomes. VOT 
might also improve treatment outcomes and reduce the 
risk of adverse events compared with DOT, because 
clinicians do not need to schedule intermittent high dose 
regimens to ensure observation.
Another limitation was the exclusion of patients with 
MDR tuberculosis from the randomised trial. This was 
done because these patients had a range of treatment 
regimens, some of which included injectable medications 
or multiple scheduled doses to be observed per day. It 
would be impractical for all these observations to be 
made through face-to-face DOT and we therefore did not 
consider there to be equipoise between VOT and DOT 
for these individuals. Patients with MDR tuberculosis 
were recruited into a separate non-randomised arm of 
the study that will be reported separately. 
The patients in this study were distributed across 
multiple sites and had many complex social needs. The 
findings are therefore likely to be generalisable to similar 
settings where patients with risk factors for non-
adherence are offered support. Although the study was 
done in a low-incidence, high-income setting, we think it 
plausible that the intervention would also be effective in 
high-incidence, low-income settings, provided that good 
internet and cellular data connections are available, as is 
the case in many urban areas in LMICs. Relative and 
Number of reports Number of patients
DOT VOT DOT (n=114) VOT (n=112)
Stomach pain, nausea, or vomiting 82 73 9 (8%) 16 (14%)
Eye problems 0 7 0 4 (4%)
Pain or swelling in face or joints 0 27 0 5 (4%)
Numbness, pain, or tingling in hands or feet 0 21 0 4 (4%)
Skin rash, severe itching, or hives 39 55 2 (2%) 6 (5%)
Headache or dizziness 9 21 2 (2%) 7 (6%)
Fever or chills 0 2 0 1 (<1%)
Unusual tiredness or loss of appetite 25 18 5 (4%) 4 (4%)
Other pain 0 144 0 13 (12%)
Not specified 29 0 3 (3%) 0
DOT=directly observed treatment. VOT=video-observed therapy.
Table 4: Adverse events by trial arm
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absolute costs of smartphones, data plans, and staff 
time differ between countries, but the large savings in 
staff time mean that VOT is likely to be cheaper than 
DOT in such settings. There is a need for more research 
in this area, including comparative studies between 
different digital adherence interventions in high-burden 
settings to measure effectiveness, feasibility with 
respect to technological infrastructure, and acceptability 
and cultural appropriateness of the interventions. Given 
the effectiveness of VOT for patients with complex 
social needs, the intervention could also be effective in 
treating other conditions that are prevalent in these 
populations; eg, hepatitis C.
There is an urgent global need for more effective and 
cheaper alternatives to DOT to enable effective ambu-
latory care of both drug-sensitive and MDR tuberculosis. 
In particular, it is important that new opportunities 
for shorter regimens for MDR tuberculosis are not 
lost because of insufficient attention to adherence.23,24 
WHO now recommends that VOT can be a suitable 
alternative to DOT and has published guidance on its 
implementation.4 VOT is, in fact, likely to be preferable 
to DOT for many patients across a broad range of 
settings, providing a more acceptable, effective, and 
cheaper option for supervision of daily and multiple daily 
doses than DOT.
Based on the experience of this trial, VOT has been 
adopted by the UK National Health Service in London 
(UK), provided by the Find and Treat service. Most 
patients with MDR tuberculosis in London are now 
treated using VOT, and many of these patients require 
multiple daily dosing (Joe Hall, Find and Treat, personal 
communication). The intervention has also been used 
successfully in children aged as young as 12 years and 
is being provided to an increasing number of patients 
outside London, particularly those with complex social 
needs. In settings such as this where mobile-internet 
connectivity makes VOT feasible, it is likely to make an 
important contribution to tuberculosis eradication.
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